New England Biolabs, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

The University of Tokyo

Clotilde K Carlow

Zhiru Li

Nathan Tanner

Yinhua Zhang

Ivan R Correa, Jr

Nicole Nichols

Guoping Ren

Gregory Patton

Eric Hunt

Esta Slayton

Catherine B Poole

Harriet M Strimpel

Andrew Barry

Antony Page

Thomas C Evans, Jr

Hiroaki Suga

James Inglese

Francine B Perler

Patricia Dranchak

Dong Ma

Hao Yu

XiaQiang Hong

Jhon Santiago Mejia

Xiqiang Hong

Ryan MacArthur

Compositions and methods are described that are directed to specific and sensitive methods of target nucleic acid detection and more specifically detecting target nucleic acids directly from biological samples. The compositions and methods were developed to be easy to use involving a minimum number of steps and giving rapid and consistent results either at point of care or in high throughput situations. The compositions and methods are directed to labelled probes and their uses in Loop-Mediated Isothermal Amplification (LAMP) diagnostic tests to detect target DNA from the environment or from an individual and also to detect specific variants of the target DNA, both with similar sensitivity. The compositions and methods may use any single improvement or combination of improvements selected from thermolabile enzyme variants, poloxamers, various salts, indicators and one or more LAMP primer sets for detecting single and/or multiple targets, probes for detecting variants of the targets including SARS-CoV-2 variants and lateral flow devices.

Rapid diagnostic test for lamp

Kits and methods are described that are directed to specific and sensitive methods of target nucleic acid detection and more specifically detecting target nucleic acids directly from biological samples. The kits and methods were developed to be easy to use involving a minimum number of steps and giving rapid and consistent results either at point of care or in high throughput situations. The kits and methods utilize in various combinations, reversible inhibitors of kit components, thermolabile enzymes, poloxamers, various salts, indicators and one or more Loop-Mediated Isothermal Amplification (LAMP) primer sets for detecting single and/or multiple targets and variants of the targets including SARS-CoV-2 targets and variants thereof in a single reaction. The kits and methods permit detection of the target nucleic with similar sensitivity regardless of the presence of undefined mutations that may enhance the virulence of cells or viruses containing the undefined mutations.

Rapid diagnostic test for LAMP

Disclosed herein are isolated peptides inhibit activity of a cofactor-independent phosphoglycerate mutase. In some examples, the isolated peptide is 6-20 amino acids long and includes the amino acid sequence of any one of SEQ ID NOs: 1-22 or 54, an analog or derivative thereof, or a pharmaceutically acceptable salt or ester thereof. In some examples, the peptide is a cyclic peptide with an N-terminal ring of 6-15 amino acids (for example, 6-10 amino acids) and a C-terminal linear portion of 1-9 amino acids (for example, 3-8 amino acids. Also disclosed h are methods of treating or inhibiting an infection in a subject, including administering to the subject an effective amount of a composition including one of more of the disclosed peptides, or analogs or derivative thereof, or pharmaceutically acceptable salts or esters thereof.

Peptide inhibitors of phosphoglycerate mutase and methods of use

The present invention relates to the use of these cyclophilins, hereinafter referred to as `tyrosine-containing` cyclophilins, in a method for identifying compounds capable of binding to and/or inhibiting the enzymatic activity of these proteins. Such compounds may be further screened for their ability to inhibit parasites which are not susceptible to the anti-parasitic effects of CsA.

Tyrosine-containing cyclophilin and related methods

The present invention relates to the use of nematode 'cyclophilin-like proteins (CLP)', in a method for identifying compounds capable of binding to and/or inhibiting the peptidyl-prolylcistransisomerase activity of these proteins. Such compounds may be further screened for their ability to inhibit nematode parasites which are not susceptible to the anti-parasitic effects of CsA.

Isolation and production of a cyclophilin-like protein endogenous to

Method for immunodiagnosis of heartworm in mammals

The present invention relates to the use of these cyclophilins, hereinafter referred to as 'cyclophilin-like proteins (CLP)' in a method for identifying compounds capable of binding to and/or inhibiting the enzymatic activity of these proteins. Such compounds may be further screened for their ability to inhibit parasites which are not susceptible to the anti-parasitic effects of CsA.

Method for identifying anti-nematode compounds

The present invention relates to the use of these cyclophilins, hereinafter referred to as 'cyclophilin-like proteins (CLP)', in a method for identifying compounds capable of binding to and/or inhibiting the enzymatic activity of these proteins. Such compounds may be further screened for their ability to inhibit parasites which are not susceptible to the anti-parasitic effects of CsA.

Method for identifying anti-parasitic compounds

Growing community of inventors

Cambridge, MA, United States of America

Clotilde K Carlow